Zura Bio Limited (NASDAQ:ZURA) Sees Significant Growth in Short Interest

Key Points

• Zura Bio Limited has experienced a significant increase in short interest, with 2,050,000 shares sold short as of September 30th, representing a 347.5% rise from mid-September.
• Analysts have varying views on Zura Bio, with a consensus price target of $11.60 and ratings ranging from "Strong Buy" to "Sell."
• On August 14th, Zura Bio reported an earnings per share of ($0.17), slightly beating the analysts' estimate of ($0.19).

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 2,050,000 shares, an increase of 347.5% from the September 15th total of 458,100 shares. Approximately 5.0% of the company's shares are sold short. Based on an average daily trading volume, of 1,660,000 shares, the days-to-cover ratio is presently 1.2 days. Based on an average daily trading volume, of 1,660,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 5.0% of the company's shares are sold short.

Analysts Set New Price Targets

Several research analysts have weighed in on ZURA shares. Chardan Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Zura Bio in a research note on Tuesday, September 30th. Oppenheimer lowered their price objective on shares of Zura Bio from $17.00 to $16.00 and set an "outperform" rating for the company in a research note on Friday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Zura Bio in a report on Tuesday. Finally, HC Wainwright dropped their price objective on shares of Zura Bio from $3.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $11.60.

Zura Bio Stock Performance

Shares of ZURA stock opened at $3.21 on Friday. The stock has a market capitalization of $208.71 million, a P/E ratio of -4.59 and a beta of 0.25. The company has a 50 day moving average price of $2.55 and a 200 day moving average price of $1.71. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $5.07.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. On average, research analysts forecast that Zura Bio will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Savant Capital LLC lifted its stake in Zura Bio by 190.4% in the second quarter. Savant Capital LLC now owns 32,409 shares of the company's stock worth $34,000 after acquiring an additional 21,249 shares during the last quarter. Bank of America Corp DE lifted its stake in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock worth $103,000 after acquiring an additional 9,966 shares during the last quarter. AQR Capital Management LLC purchased a new position in Zura Bio in the first quarter worth approximately $72,000. Nuveen LLC purchased a new position in Zura Bio in the first quarter worth approximately $76,000. Finally, Jane Street Group LLC purchased a new position in Zura Bio in the second quarter worth approximately $113,000. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.